The global Smart Insulin Pens Market is experiencing substantial growth, driven by the increasing prevalence of diabetes, ...
Market OverviewThe Global Smart Insulin Pens Market was valued USD 102.86 Million in 2022 and is anticipated to reach a value ...
Interesting Engineering on MSN12d
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatmentThe FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...
Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.
Soliqua 100/33 (insulin glargine/lixisenatide) is a prescription drug that’s used to treat type 2 diabetes. Soliqua 100/33 comes as a prefilled single-use pen for injecting the drug under your skin.
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback